CYCN - Cyclerion gains after announcing upcoming presentation of Alzheimer's study design

Cyclerion Therapeutics (CYCN) added ~15.8% in after-hours on its announcement of an upcoming presentation on the clinical trial design of CY6463, its candidate for Alzheimer’s disease.At the Alzheimer’s Association International Conference 2021 ((AAIC)) to be held July 26 – 30, the company is set to present details on the design of the Phase 2a study of its lead development candidate, CY6463 in participants with Alzheimer’s disease with vascular pathology.A penetrant of the central nervous system ((CNS)), orally administered CY6463 is being studied as a disease-modifying therapy for a range of CNS diseases.In May, announcing the publication of pre-clinical results of CY6463, Cyclerion said that the administration of the experimental therapy in a range of animal models led to meaningful levels of the drug in cerebrospinal fluid with neurological effects.

For further details see:

Cyclerion gains after announcing upcoming presentation of Alzheimer’s study design